- Home
- FTI vs BBIO Comparison
FTI vs BBIO Comparison
Compare FTI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | BBIO |
|---|---|---|
| Founded | 1884 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 14.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FTI | BBIO |
|---|---|---|
| Price | $45.28 | $74.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $45.60 | ★ $74.79 |
| AVG Volume (30 Days) | ★ 2.6M | 2.0M |
| Earning Date | 10-23-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 59.09 | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $9,803,000,000.00 | $353,780,000.00 |
| Revenue This Year | $10.34 | $128.44 |
| Revenue Next Year | $7.23 | $76.14 |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | 11.44 | ★ 62.46 |
| 52 Week Low | $22.12 | $25.34 |
| 52 Week High | $47.33 | $75.10 |
Technical Indicators
Market Signals| Indicator | FTI | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 72.05 |
| Support Level | $44.93 | $72.38 |
| Resistance Level | $47.33 | $75.04 |
| Average True Range (ATR) | 1.15 | 2.44 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 56.26 | 92.19 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.